Based on the natural targeting potential of platelet to circulating tumor cells, researchers developed an in situ sprayable chemo-immunotherapy gel that acts as a drug reservoir and releases both anti-PDL1 monoclonal antibody and platelet-derived tiny extracellular vesicles combined with doxorubicin (PexD), an anticancer drug that prevents post-surgery tumor recurrence and spread [112]. This evidence concerns the gene CD274 and neoplasm.